ANKERE THERAPEUTICS
Ankere is striving to develop transformative therapies based on excellent science that will enable people to live long and healthy lives.
ANKERE THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Address:
Melbourne, Victoria, Australia
Country:
Australia
Status:
Active
Total Funding:
10 M AUD
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Baudax Bio
Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Halo Labs
Halo Labs is a biotechnology company that specializes in analytical instrumentation and biopharma.
TCR2
TCR2 is a discovery stage pharmaceutical company that developed a unique proprietary TRuCâ„¢ platform.
Tribune Therapeutics
Tribune Therapeutics specializes in building promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.
Current Advisors List
Investors List
Brandon Capital
Brandon Capital investment in Seed Round - Ankere Therapeutics
IP Group
IP Group investment in Seed Round - Ankere Therapeutics
More informations about "Ankere Therapeutics"
Ankere Therapeutics | Monash University
Ankere Therapeutics is developing new therapies which target inflammatory diseases, particularly those affecting the lung. It is based on research led by Monash with collaborators at University of South Australia and backed by IP …See details»
Home - Ankyra Therapeutics
Ankyra is developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response.See details»
Ankere Therapeutics (Ankerx Pty Ltd) - VentureRadar
Neurophth is a Chinese biotech developing gene therapeutics for ophthalmological diseases. Neurophth was founded by Prof Bin Li's team at Wuhan Tongji Hospital in 2016. Ankere is …See details»
Ankere Therapeutics - Growth Outlook - Crunchbase
Ankere Therapeutics company focused on developing new pharmaceutical agents that target inflammatory conditions.See details»
Australian collaboration and AU$10m investment fuels Ankere ...
May 3, 2022 Australian biotech company, Ankere Therapeutics (‘Ankere’), has launched with AU$10 million seed investment to develop new therapies which target inflammatory diseases, …See details»
Ankere Therapeutics - 2025 Company Profile & Team - Tracxn
Jun 20, 2025 Ankere Therapeutics - CRO focused on preclinical development of diversified therapeutics. Raised a total funding of $7.17M over 1 round from 2 investors.See details»
Monash researcher founding scientist of new biotech …
May 3, 2022 A researcher from the Monash Institute of Pharmaceutical Sciences (MIPS) is a co-founder of Australian biotech company, Ankere Therapeutics (‘Ankere’), which has launched with AU$10 million seed …See details»
Ankere Therapeutics Pty Ltd. - Drug pipelines, Patents, Clinical …
Explore Ankere Therapeutics Pty Ltd. with its drug pipeline, therapeutic area, technology platform, .See details»
Ankere Therapeutics - Techboard
09/06/202216/01/2024 Peter van Bruchem Uncategorised Company Owned Profile: No Login to Take Ownership Company ProfileSee details»
Investment in Australian collaboration targeting inflammatory lung ...
May 3, 2022 A new Australian biotechnology company with the launch of Ankere Therapeutics on the back of a $10 million seed investment. The company will focus on the development of …See details»
OnKure Therapeutics
OnKure Therapeutics - Writing the Next Chapter in Precision Medicines for Patients With CancerSee details»
Biotech startup Ankere Therapeutics lands $10 million Seed round …
May 3, 2022 Biotech startup Ankere Therapeutics has raised $10 million in Seed capital to develop new therapies targeting inflammatory diseases, especially in the lungs. The funding …See details»
Ananke Therapeutics 2025 Company Profile: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Ananke Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Ankere Therapeutics–SEVERAL: investment, 202205 seed financing …
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«See details»
Our impact - Monash Institute of Pharmaceutical Sciences
Ankere Therapeutics Ankere Therapeutics, a new company based on research by MIPS medicinal chemists in partnership with the University of South Australia’s Centre for Cancer Biology, …See details»
Ankere Therapeutics - Funding & Investors - Tracxn
Jun 20, 2025 Ankere Therapeutics has raised a total funding of $7.17M over 1 round from 2 investors. Investors include IP Group and Brandon Capital. Their latest funding round was of …See details»
$10 million investment fuels promising treatments for …
May 3, 2022 Ankere Therapeutics ‘Ankere’ is venture-backed company focused on developing new pharmaceutical agents that target inflammatory conditions, particularly those of the lung.See details»
Ankere therapeutics – IP Group Australia
Ankere therapeuticsOur portfolioAnkere therapeuticsSee details»
Congratulations to Associate Professor Bernard Flynn on the
Congratulations to Associate Professor Bernard Flynn on the launch of Ankere Therapeutics, a new Australian biotech company dedicated to the development of new therapies that target …See details»
Ankyra Therapeutics Announces Expansion of Existing …
JANUARY 10, 2025 (CAMBRIDGE, MA) – Ankyra Therapeutics, a clinical-stage biotech company developing anchored drug conjugates for the treatment of cancer, today announced an …See details»